7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug DevelopmentCybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory BoardEntheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Third Wave.Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004Rritual Superfoods Ready to Launch Amazon Store in USAAtai Life Sciences Is Setting The Stage For The Largest IPO The Psychedelics Sector Has Seen To DateEntheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available fMajor U.S. States Are Taking A Serious Look At Decriminalizing Psychedelic Compounds For The Treatment Of Mental Illness
Back

Rojo Resources Ltd. Announces Closing of Subscription Receipt Offering, Salvation Botanicals Closes Sidecar Private Placement – Aggregate Gross Proceeds of $6,000,000 Raised

Apr 7, 2020 • 12:22 PM EDT
4 MIN READ  •  By Anthony Varrell
Share Share - Facebook Share - Twitter

Rojo Resources Ltd. (TSXV: RJ:H) is pleased to announce that it has closed its previously announced private placement of subscription receipts.  The private placement was over-subscribed and raised gross proceeds of $5,745 ,000. In addition to proceeds raised by Rojo under the Offering, the target company of Rojo’s proposed reverse takeover Salvation Botanicals Ltd. has also completed a non-brokered private placement of 1,020,000 units for gross proceeds of $255,000, for aggregate gross Offering and Sidecar proceeds of $6,000,000 .

Rojo issued 45,960,000 subscription receipts (the “Subscription Receipts“) at a price of $0.125 per Subscription Receipt ( $0.25 per Subscription Receipt on a post-consolidation basis, with reference to the Company’s previously announced 2:1 common share consolidation).  The gross proceeds from the Offering will be held in escrow by Computershare Trust Company of Canada and will be released upon completion of the escrow release conditions, which include completion of the Company’s acquisition by plan of arrangement of Salvation, which includes Salvation’s wholly-owned subsidiary, Numinus Wellness Inc. (“Numinus“). The entity resulting from the acquisition is referred to as the “Resulting Issuer”.

The Resulting Issuer aims to operate at the forefront of the transformative change in treating the growing prevalence of mental health issues and desire for greater overall wellness through regulated alternative medicine therapies including the use of cannabinoids and, subject to regulatory approval, psychedelic drug treatments. The Resulting Issuer has an established and integrated treatment and healing centre with the goal of creating a model to scale globally.

The Resulting Issuer proposes to deploy the additional working capital provided by the substantial oversubscription of the Offering and Sidecar to:

(i)

upgrade its existing integrated treatment and healing centre, as well as expand the network of centres through acquisitions of existing facilities;

(ii)

upgrade Salvation’s existing laboratory and processing facilities;

(iii)

finance the completion of Salvation’s cannabis sales license application process with Health Canada;

(iv)

build a comprehensive research and development facility to advance the growth and sophistication of both Salvation and Numinus’ offerings;

(v)

engage the growing community of experts in psychedelic therapy protocol developments to enhance and grow the scope of Numinus’ services, and provide additional training to Numinus’ staff in respect of same;

(vi)

to fund strategic partnerships aimed at developing a model that uses research, therapies and technology to advance public health and wellness; and

(vii)

for general working capital.

In connection with the plan of arrangement, pursuant to which Rojo will acquire Salvation (including its wholly-owned subsidiary Numinus), the Company will prepare and file a filing statement on TSX Venture Exchange Form 3D2 (the “Filing Statement“). When available under the Company’s profile at www.sedar.com, investors are encouraged to review the entirety of the Filing Statement for greater detail in respect of the business of the Company, business of Salvation, the proposed business of the Resulting Issuer and the use of proceeds discussed above.

As a result of the 2:1 common share consolidation, each two Subscription Receipts represents the right to automatically receive, upon closing of the Company’s proposed plan of arrangement, one unit of the Resulting Issuer, each unit comprising one common share and one-half of one share purchase warrant (the “Warrants“). Each Warrant will entitle the holder to acquire for a period of 2 years, one common share at a price of 50 cents per share, subject to accelerated expiry. The Warrants contain an accelerator clause whereby, if at any time after the date of issuance and prior to the expiry of the Warrants the volume-weighted average trading price of the common shares exceeds 75 cents for a period of 10 consecutive trading days, the Resulting Issuer is entitled, at its option, to accelerate the expiry date of the Warrants by delivering written notice to the holders of Warrants, to a date that is not less than 30 days following the delivery of such written notice. The Salvation Units issued under the Sidecar are each comprised of one common share of Salvation, and one warrant of Salvation having the same terms as the Warrants. All securities of Salvation issued in the Sidecar will be included in the previously announced acquisition of Salvation by Rojo on a 1:1 basis.

The Company has agreed to pay certain finder’s fees in connection with the Offering. The finder’s fees are not payable until the escrow release conditions are met, being the closing of the Company’s acquisition of Salvation.

ON BEHALF OF THE BOARD

Rojo Resources Ltd.

Allen Morishita
President and Chief Executive Officer

For further information contact:

Michael Tan
Chief Operating Officer at Salvation/Numinus
1-855-420-8617

Share Share - Facebook Share - Twitter

Tags

Authored By

Anthony Varrell

Anthony Varrell is Managing Director of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link